We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Margins Face Tariff Pressure: Is ISRG's Profitability at Risk?
Read MoreHide Full Article
Key Takeaways
ISRG posted strong revenue and earnings growth but saw a 90-bp gross-margin hit due to tariffs.
Management now guides 2025 gross margin of 67-67.5% on better cost leverage and a smaller tariff impact.
Scaling da Vinci 5 and Ion, cost cuts and new distribution in Europe are key to stabilizing ISRG's margins.
Intuitive Surgical’s (ISRG - Free Report) strong third-quarter results — 23% revenue growth and 30% earnings growth—came with one major flaw: margin pressure. Pro forma gross margin slipped 90 basis points (bps) year over year to 68%, squeezed by a trifecta of structural and near-term headwinds: tariffs, an unfavorable cost mix tied to da Vinci 5 and Ion, and higher facility expenses. Tariffs alone accounted for the full 90-bp drag, with additional pressure from lower-margin platform mix and elevated service costs, partly offset by internal cost-reduction efforts.
However, management has lifted its gross-margin outlook to 67–67.5% for 2025, citing stronger fixed-cost leverage and better-than-expected cost reductions, as well as a smaller full-year tariff hit—now pegged at 70 bps. But fourth-quarter gross margin is expected to dip slightly below 67%, raising investor concerns that the mix and spending trend may continue to weigh on profitability.
Although margin pressure is likely to continue, the company is working on several initiatives that are expected to offset the pressure. First, cost-reduction initiatives—already cushioning the third-quarter impact—should rise as manufacturing scale grows alongside rapid da Vinci 5 adoption. Second, direct distribution in Italy, Spain and Portugal, beginning in the first half of 2026, is expected to be slightly accretive to earnings.
Meanwhile, platform mix will be a critical swing factor. da Vinci 5 and Ion continue to scale rapidly, but both carry lower margins today. As volumes increase and cost curves bend, these platforms could transition from margin dilutive to neutral—or even accretive—over time.
So, can ISRG sustain margins above 67% long term? The answer hinges on tariff resolution, mix normalization and execution of cost programs. For now, the company appears positioned to defend margins at or slightly above the high-67% range, but sustained expansion will require more help from operating leverage, and less from tariffs.
Peers Facing Tariff Pressure
Medtronic (MDT - Free Report) delivered accelerating revenue and earnings growth, but profitability remains pressured by tariffs and mix. MDT repeatedly highlighted tariff headwinds, with fiscal second-quarter gross margin carrying a 20-bp drag and full-year fiscal 2026 expected to absorb nearly $185 million in tariff costs. While MDT expanded gross margin by 70 bps operationally, negative mix from Cardiac Ablation and Diabetes diluted gains. MDT emphasized that pricing and cost-efficiency programs continue to offset part of the pressure, yet operating margin is still guided to decline nearly 50 bps, including tariffs. MDT maintains that sustained cost actions and scale should support margin stability as growth drivers gain traction.
Stryker (SYK - Free Report) again posted strong top-line momentum, but tariffs remain a meaningful profitability constraint. SYK noted that tariff pressure in the third quarter increased significantly sequentially, with gross margin facing nearly $200 million full-year impact despite still expanding 50 bps on mix and cost improvements. SYK stressed that disciplined SG&A control and manufacturing optimization helped lift operating margin by 90 bps, but in the absence of tariff burden, margin expansion would have been even stronger. SYK repeatedly emphasized its ability to outrun tariff pressure through pricing, mix and scale, arguing that its diversified portfolio and sustained 9–10% organic growth position SYK to defend profitability even as tariffs escalate year over year.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have gained 9.2% in the year-to-date period compared with a 4.2% rise for the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 60.09, above the industry average. But it is still lower than its five-year median of 71.54. ISRG carries a Value Score of F.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2025 earnings implies a 17.3% rise from the year-ago period’s level.
Image: Shutterstock
Margins Face Tariff Pressure: Is ISRG's Profitability at Risk?
Key Takeaways
Intuitive Surgical’s (ISRG - Free Report) strong third-quarter results — 23% revenue growth and 30% earnings growth—came with one major flaw: margin pressure. Pro forma gross margin slipped 90 basis points (bps) year over year to 68%, squeezed by a trifecta of structural and near-term headwinds: tariffs, an unfavorable cost mix tied to da Vinci 5 and Ion, and higher facility expenses. Tariffs alone accounted for the full 90-bp drag, with additional pressure from lower-margin platform mix and elevated service costs, partly offset by internal cost-reduction efforts.
However, management has lifted its gross-margin outlook to 67–67.5% for 2025, citing stronger fixed-cost leverage and better-than-expected cost reductions, as well as a smaller full-year tariff hit—now pegged at 70 bps. But fourth-quarter gross margin is expected to dip slightly below 67%, raising investor concerns that the mix and spending trend may continue to weigh on profitability.
Although margin pressure is likely to continue, the company is working on several initiatives that are expected to offset the pressure. First, cost-reduction initiatives—already cushioning the third-quarter impact—should rise as manufacturing scale grows alongside rapid da Vinci 5 adoption. Second, direct distribution in Italy, Spain and Portugal, beginning in the first half of 2026, is expected to be slightly accretive to earnings.
Meanwhile, platform mix will be a critical swing factor. da Vinci 5 and Ion continue to scale rapidly, but both carry lower margins today. As volumes increase and cost curves bend, these platforms could transition from margin dilutive to neutral—or even accretive—over time.
So, can ISRG sustain margins above 67% long term? The answer hinges on tariff resolution, mix normalization and execution of cost programs. For now, the company appears positioned to defend margins at or slightly above the high-67% range, but sustained expansion will require more help from operating leverage, and less from tariffs.
Peers Facing Tariff Pressure
Medtronic (MDT - Free Report) delivered accelerating revenue and earnings growth, but profitability remains pressured by tariffs and mix. MDT repeatedly highlighted tariff headwinds, with fiscal second-quarter gross margin carrying a 20-bp drag and full-year fiscal 2026 expected to absorb nearly $185 million in tariff costs. While MDT expanded gross margin by 70 bps operationally, negative mix from Cardiac Ablation and Diabetes diluted gains. MDT emphasized that pricing and cost-efficiency programs continue to offset part of the pressure, yet operating margin is still guided to decline nearly 50 bps, including tariffs. MDT maintains that sustained cost actions and scale should support margin stability as growth drivers gain traction.
Stryker (SYK - Free Report) again posted strong top-line momentum, but tariffs remain a meaningful profitability constraint. SYK noted that tariff pressure in the third quarter increased significantly sequentially, with gross margin facing nearly $200 million full-year impact despite still expanding 50 bps on mix and cost improvements. SYK stressed that disciplined SG&A control and manufacturing optimization helped lift operating margin by 90 bps, but in the absence of tariff burden, margin expansion would have been even stronger. SYK repeatedly emphasized its ability to outrun tariff pressure through pricing, mix and scale, arguing that its diversified portfolio and sustained 9–10% organic growth position SYK to defend profitability even as tariffs escalate year over year.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have gained 9.2% in the year-to-date period compared with a 4.2% rise for the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 60.09, above the industry average. But it is still lower than its five-year median of 71.54. ISRG carries a Value Score of F.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2025 earnings implies a 17.3% rise from the year-ago period’s level.
Image Source: Zacks Investment Research
The company currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.